PharmaCell to Finalize Purchase of Cell Therapy Production Facility - - BioPharm International

ADVERTISEMENT

PharmaCell to Finalize Purchase of Cell Therapy Production Facility



PharmaCell, a CMO for cellular therapies and regenerative medicine in Europe, has finalized its purchase of the cell therapy production facility from TiGenix, a cell therapy company. TiGenix has manufactured ChondroCelect, a product for cartilage repair, at its site in Sittard-Geleen, The Netherlands, since the beginning of 2013. ChondroCelect will continue to be manufactured at the facility as before under a long-term CMO agreement with TiGenix.

Following the acquisition, PharmaCell will continue to operate its Maastricht facility in addition to the site at Sittard-Geleen. The Maastricht facility offers non-GMP process development and GMP-production facilities for early- to mid-stage clinical trials in cell therapy. The Geleen facility will offer clients the opportunity to support late stage clinical trials and commercial production for the industry.

Source: PharmaCell

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines

Click here